Drugs / Quadrivalent cell-culture based influenza vaccin
Quadrivalent cell-culture based influenza vaccin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02249221 | Oct → Nov 2014 | influenza | Green Cross Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent cell-culture based influenza vaccin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02249221 ↗ |
| Modality | Vaccine | “GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)” NCT02249221 ↗ |
| Route | Intramuscular | “GC3106, 0.5ml, intramuscular, a single dosing at Day 1” NCT02249221 ↗ |